News

Back to All News

Kindred Biosciences, Inc. (KIN) - Initiation of Research Coverage

July 23, 2018

Lake Street Capital Markets Analyst Brooks O’Neil initiated coverage of Kindred Biosciences, Inc. (KIN), with a BUY rating and price target of $30.00 (KIN $12.85). Kindred is a biopharmaceutical company focused on developing medicines for cats, dogs and horses.

Contact Us

Phone
612.326.1305

US Mail
920 Second Avenue South
Suite 700
Minneapolis, MN 55402

Email
Email Us

Find Us